HbA1c variability supplement revised- AP 052420 .pdf (945.98 kB)

Association of Long-Term Change and Variability in Glycemia with Risk of Incident Heart Failure among Patients with Type 2 Diabetes Mellitus – A Secondary Analysis of the ACCORD Trial

Download (945.98 kB)
posted on 17.06.2020 by Matthew W. Segar, Kershaw V. Patel, Muthiah Vaduganathan, Melissa C. Caughey, Javed Butler, Gregg C. Fonarow, Justin L. Grodin, Darren K. McGuire, Ambarish Pandey
Objective: Evaluate the associations between long-term change and variability in glycemia with risk of HF among patients with T2DM.

Research Design and Methods: Among participants with T2DM enrolled in the ACCORD trial, variability in HbA1c was assessed from stabilization of HbA1c following enrollment (8 months) to 3 years of follow-up as follows: average successive variability (ASV=average absolute difference between successive values), coefficient of variation (CV=standard deviation/mean), and standard deviation. Participants with HF at baseline or within 3 years of enrollment were excluded. Adjusted Cox models were used to evaluate the association of % change (from baseline to 3 years of follow-up) and variability in HbA1c over the first 3 years of enrollment and subsequent risk of HF.

Results: The study included 8,576 patients. Over a median follow-up of 6.4 years from the end of variability measurements at year 3, 388 patients had an incident HF hospitalization. Substantial changes in HbA1c were significantly associated with higher risk of HF [HR (95% CI) for ≥10% decrease = 1.32 (1.08-1.75), ≥10% increase = 1.55 (1.19-2.04), ref: <10% change in HbA1c]. Higher long-term variability in HbA1c was significantly associated with higher risk of HF [HR (95% CI) per 1 SD of ASV = 1.34 (1.17-1.54)] independent of baseline risk factors and interval changes in cardiometabolic parameters. Consistent patterns of association were observed using alternative measures of glycemic variability.

Conclusions: Substantial long-term changes and variability in HbA1c were independently associated with risk of HF among patients with T2DM.



Logo branding